Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press Releases

Incyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)

  • The Pharma Data
  • July 3, 2025

Incyte Grants Equity Awards to Incoming CEO Bill Meury Under Nasdaq Rule 5635(c)(4) Incyte Corporation (Nasdaq: INCY) announced the grant of equity inducement awards to Bill Meury, marking a key…

Read MoreIncyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
  • Regulatory

FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma

  • The Pharma Data
  • July 3, 2025

FDA Grants Accelerated Approval to Regeneron’s Lynozyfic™ (linvoseltamab-gcpt) for Relapsed or Refractory Multiple Myeloma Regeneron Pharmaceuticals has secured a critical milestone in oncology drug development with the U.S. Food and…

Read MoreFDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma
  • Regulatory

FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial

  • The Pharma Data
  • July 3, 2025

FDA Grants Priority Review to Merck’s WINREVAIR™ Based on Landmark ZENITH Trial Showing Dramatic Reduction in Morbidity and Mortality in PAH Patients Merck (NYSE: MRK), operating as MSD outside the…

Read MoreFDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
  • Business

Gilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind

  • The Pharma Data
  • July 2, 2025

Gilead Targets HIV Prevention Dominance With Twice-Yearly Yeztugo as GSK Mounts a Defense Gilead Sciences is taking a bold step to further entrench itself as the dominant force in HIV…

Read MoreGilead Advances in HIV Market With Twice-Yearly Yeztugo, Leaving GSK Behind
  • Press Releases

Lupin Unveils New Consumer Healthcare Arm: LupinLife

  • The Pharma Data
  • July 2, 2025

Lupin Launches LupinLife as Independent Subsidiary to Strengthen Focus on India’s Self-Care Market Global pharmaceutical leader Lupin Limited has announced a significant strategic move to bolster its consumer healthcare operations.…

Read MoreLupin Unveils New Consumer Healthcare Arm: LupinLife
  • Research

WHO-backed testing model boosts mpox, HIV, and syphilis response

  • The Pharma Data
  • July 2, 2025

As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing…

Read MoreWHO-backed testing model boosts mpox, HIV, and syphilis response
  • News

Suriname Officially Certified Malaria-Free by WHO

  • The Pharma Data
  • July 2, 2025

Suriname Becomes First Amazon Nation to Earn WHO Malaria-Free Certification In a historic public health milestone, the Republic of Suriname has been officially certified as malaria-free by the World Health…

Read MoreSuriname Officially Certified Malaria-Free by WHO
  • Regulatory

Jazz Pharma Gets EU Nod for Ziihera in Advanced HER2+ Biliary Cancer

  • The Pharma Data
  • July 2, 2025

Jazz Pharmaceuticals Secures Conditional EU Approval for Ziihera® (zanidatamab) to Treat Advanced HER2-Positive Biliary Tract Cancer Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that the European Commission (EC) has granted…

Read MoreJazz Pharma Gets EU Nod for Ziihera in Advanced HER2+ Biliary Cancer
  • Press Releases

WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics

  • The Pharma Data
  • July 2, 2025

WuXi Biologics Launches WuXiHigh™ 2.0 to Advance High-Concentration Biologic Formulations WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the official launch of WuXiHigh™…

Read MoreWuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics
  • News

BioMarin Completes Acquisition of Inozyme Pharma

  • The Pharma Data
  • July 2, 2025

BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has officially completed the acquisition of Inozyme Pharma, Inc. (Nasdaq: INZY), a move…

Read MoreBioMarin Completes Acquisition of Inozyme Pharma
  • Press Releases

Genmab Unveils Executive Committee Restructuring

  • The Pharma Data
  • July 2, 2025

Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer…

Read MoreGenmab Unveils Executive Committee Restructuring
  • Research

argenx Advances ARGX-119 for Congenital Myasthenic Syndromes

  • The Pharma Data
  • July 2, 2025

argenx Advances ARGX-119 into Registrational Study for Congenital Myasthenic Syndromes Following Positive Phase 1b Data argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for…

Read Moreargenx Advances ARGX-119 for Congenital Myasthenic Syndromes
Next

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: [email protected]

Latest Posts

  • Incyte Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
  • FDA Grants Accelerated Approval to Lynozyfic™ for Relapsed or Refractory Multiple Myeloma
  • FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2025 | The Pharma Data | All Rights Reserved.